ReviewCureus2025
Comparative Efficacy of Bupivacaine Versus Ropivacaine for Postoperative Pain Control After Total Knee Arthroplasty: A Systematic Review and Meta-Analysis.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Liposomal bupivacaine in peri-articular injection reduces opioid consumption and improves early prognosis of total knee arthroplasty: a randomized controlled trial.BMC musculoskeletal disorders · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postoperative pain is a significant challenge that can delay early mobilization and prolong hospitalization after total knee arthroplasty (TKA). Effective pain management is critical to promote rehabilitation, reduce opioid consumption, and improve long-term patient outcomes. Bupivacaine and ropivacaine are widely utilized local anesthetics administered by way of peripheral nerve blocks, periarticular injections, and epidural anesthesia to help manage postoperative pain. This systematic review and meta-analysis aimed to compare postoperative pain levels after administering bupivacaine or ropivacaine via peripheral nerve blocks or periarticular injections. Secondary outcomes included length of stay (LOS), rescue analgesia, and motor blockade. Subgroup analysis was performed to differentiate between drug administration by way of peripheral nerve blocks and periarticular injections. A total of nine studies and 656 patients were included. There was no difference in pain levels at 6 hours (MD = 0.12, 95% CI, -0.41 to 0.65, P = 0.66), 12 hours (MD = - 0.01, 95% CI, -0.62 to 0.61, P = 0.98), and 24 hours postoperative (MD = 0.17; 95% CI, -0.27 to 0.61, P = 0.46) between peripheral nerve blocks and periarticular injections of bupivacaine and ropivacaine. At 72 hours postoperative, ropivacaine decreased pain levels when administered through peripheral nerve block only (MD = 0.82, 95% CI, 0.55 to 1.09, P = 0.002). There were no differences in LOS or rescue analgesia, but bupivacaine provided a greater degree of motor nerve blockade (MD = 0.18, 95% CI, 0.01 to 0.35, P = 0.04) assessed by the classical Bromage scale. The findings suggest that bupivacaine and ropivacaine provide comparable analgesic efficacy for postoperative pain control following TKA, indicating that the drug of choice may be due to secondary factors, including cost, availability, or provider preference.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.